Aurex uses its mother company’s state of the art manufacturing sites (Aurobindo). Production of intermediates, API’s and finished dosage forms, as well as packaging of finished products is carried out in-house.
We have close to 20 manufacturing facilities in India , US and Brasil. The sites are approved by all major regulatory authorities, such as UK MHRA, US FDA, Brasil ANVISA, Australia TGA, South Africa MCC and Canada Health. These approvals allow us to supply products to customers globally.
A few highlights of our capacities:
- unit 4: 20,000 sqm state of the art site for lyophilized and powder injections, prefilled syringes, opthalmics and low volume parenterals.
- unit 6: 58,000 sqm dedicated cephalosporin oral and sterile production site
- unit 7: ultra modern unit based on the suite manufacturing concept for huge capacities
- unit 12: 15,000 sqm dedicted betalactam oral and sterile manufacturing location
Being part of one the largest vertically integrated pharma companies, we are in a unique position to offer advantages regarding costs, quality and supply chain to our clients.